Multimodality Therapies for Localized Prostate Cancer

By sjmartinez • February 2, 2023

Valle LF, Jiang T, Weiner AB, Reiter RE, Rettig MB, Shen J, Chang AJ, Nickols NG, Steinberg ML, Kishan AU. Multimodality Therapies for Localized Prostate Cancer. Curr Oncol Rep. 2023 Feb 1. doi: 10.1007/s11912-023-01374-9. Epub ahead of print. PMID: 36723856.

Tags: ADT, Genomics, Hematology/Oncology, hormone therapy, Localized prostate cancer, Publications, Radiation, radical prostatectomy, Radiotherapy, SBRT, Surgery, Veterans Administration

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]

Long-Term Survival After Percutaneous Image-Guided Thermal Ablation of Oligometastatic Renal Cell Carcinoma

Kim DH, Keshavarz P, Tibbe TD, Suh RD, Abtin F, Genshaft SJ, Drakaki A, Shuch BM, Pantuck AJ, Lu DS, Raman SS. Long-Term Survival After[...]

Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma

Mar N, Cabral MY, Go J, Kaakour D, Dwabe S, Seyedin SN, Drakaki A. Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without[...]